Elbit Medical Technologies

Tel Aviv Stock Exchange: EMTC

NIS90.1m market cap

NIS0.92 last close

Elbit Medical Technologies is an Israeli biomedical and healthcare technology group. Its portfolio of two companies is focused on medical devices and therapeutics: InSightec, which develops and markets the ExAblate platform for non-invasive thermal tissue ablation, and Gamida Cell, which is developing a universal bone marrow transplant.

Investment summary

Elbit Medical’s holding Gamida Cell recently reported data from its 125-patient Phase III study of omidubicel in patients with haematological malignancies undergoing bone marrow transplants. The median time to neutrophil engraftment was 12 days for omidubicel patients compared to 22 days for those receiving standard umbilical cord blood (p<0.001). Gamida Cell expects to initiate the rolling biologic licence application (BLA) submission in Q420 and launch in 2021.

Y/E Dec
Revenue (US$m)
EBITDA (US$m)
PBT (US$m)
EPS (c)
P/E (x)
P/CF (x)
2018A 35.0 34.0 26.8 0.12 220.5 N/A
2019A 16.8 0.4 (21.2) (0.09) N/A N/A
2020E N/A N/A N/A N/A N/A N/A
2021E N/A N/A N/A N/A N/A N/A
Industry outlook

Elbit Medical Technologies is invested in the healthcare sector through its holdings in two companies that are developing medical device and therapeutic technologies.

Last updated on 26/06/2020
Register to receive research on Elbit Medical Technologies as it is published
Sector
Healthcare
Share price graph
Balance sheet
Forecast net debt (US$m) N/A
Forecast gearing ratio (%) N/A
Price performance
%
1m
3m
12m
Actual (20.7) 1.7 12.9
Relative* (13.0) (3.6) 27.0
52-week high/low NIS1.4/NIS0.7
*% relative to local index
Key management
Yael Edri CFO